Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
Oncology
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Dr Judith Balmaña
Dr Rebecca Dent
Prof. Simon Boulton
Prof. Sibylle Loibl
Prof. Eric Pujade-Lauraine
Prof. Charlie Gourley
Dr Violeta Serra
Prof. Jonathan A. Ledermann
Publication Date
Sep 2021
Dr Judith Balmaña has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca.
Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.
Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Artios Pharma Ltd.
Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
Dr Violeta Serra has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca and Tesaro.
Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
Programme summary
Duration 10 MIN
Downloadable resources Yes-
DOWNLOAD THE SLIDES
-
Language(s)
Share this programme
Other programmes of interest
Video
Oncology
Recent advances in precision oncology and future implications
Two emerging and two established targets
Experts
Prof. David Hong-
Downloadable
Resources -
4 MIN
-
Dec 2024
Publication
Oncology
Survey on the evolving role of the oncology nurse in the USA
Announcing the publication of survey results
Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo-
Downloadable
Resources -
10 MIN
-
Dec 2024
Video
Oncology
Elacestrant in ER+/HER2- metastatic breast cancer
An expert overview of the EMERALD subgroup analysis
Experts
Dr Virginia Kaklamani-
Downloadable
Resources -
4 MIN
-
Dec 2024
Video
Oncology
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)
Managing patients with nccRCC: guidelines, recommendations, and best practice
Experts
Prof. Laurence AlbigesEndorsed by
-
Downloadable
Resources -
4 MIN
-
Dec 2024
Micro learning
Oncology
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment
Risk factors, diagnostic tools and treatment options for different patient groups
Experts
Prof. Efrat Dotan, Prof. Shubham PantEndorsed by
-
Downloadable
Resources -
4 MIN
-
Dec 2024
Conference update
Oncology
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update
Exploring emerging treatment strategies presented at SABCS 2024
Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava-
Downloadable
Resources -
5 MIN
-
Dec 2024
